Naveen Pemmaraju, Director of Leukemia-Cancer Network, Executive Director of Cancer Medicine, Director of BPDCN at the Department of Leukemia, and Professor at the Department of Leukemia at MD Anderson Cancer Center, shared a post on X about a paper he co-authored with colleagues, published in ScienceDirect:
”Just out in Pubmed – Ph 1-2 results of Tagraxofusp monotherapy in R/R Myelofibrosis (MF).
Blood Journals Portfolio MPN led by Dr. Abdulraheem Yacoub and Naveen Pemmaraju.”
Title: Final safety and efficacy results from a phase 1/2 study of tagraxofusp, a CD123-targeted therapy, for myelofibrosis
Authors: Abdulraheem Yacoub, Haris Ali, Vikas Gupta, Eunice S. Wang, Mrinal M. Patnaik, Gary J. Schiller, Minakshi Taparia, Tariq I. Mughal, Ross Lindsay, Antonio Galleu, Ira Gupta, Naveen Pemmaraju
Read the Full Article.
More posts featuring Naveen Pemmaraju.
